Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Annals of oncology : official journal of the European Society for Medical Oncology, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası:
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.annonc.2026.10.1281
- Dergi Adı: Annals of oncology : official journal of the European Society for Medical Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet